Skip to main content

FRAME - tumor genome-based personalized anti-cancer vaccines off-the-shelf

Project description

Frame-shift mutation based anticancer vaccination

Immunotherapy shows impressive potential for cancer treatment. This approach involving the general activation of the immune system would benefit dramatically if combined with tumour-specific vaccination. This is now possible with technology enabling routine sequencing of the entire tumour DNA within two weeks. Frame Cancer Therapeutics has developed a new kind of personalised anticancer vaccine based on shared neoantigens induced by frameshift mutations. These sequences are not normally expressed, and are thus attacked by the immune system, enabling specific vaccines for different tumour types. The EU-funded project focuses on the development of specific sets of vaccines for cancers according to their shift-mutations, providing an effective and less-expensive approach compared to point-mutation based neoantigen vaccination.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

FRAME PHARMACEUTICALS BV
Net EU contribution
€ 50 000,00
Address
Science Park 106
1098 XG Amsterdam
Netherlands

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00